Message #8 From:
NewsBot Date: September 7, 2005 11:00:00 PM
XNOM News Xenomics' Novel Noninvasive Tr-DNA Technology Featured as Potential ``Amnio Alternative'' in Online News Article; Company CEO Dr. Randy White Discusses Breakthrough Medical Technology for Prenatal Diagnostic Testing in ``Herald News''
NEW YORK--(BUSINESS WIRE)--Sept. 8, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has been featured in the online news source the "Herald News," about its novel, noninvasive medical diagnostic testing technology, with applications designed for the safe and accurate detection of prenatal Down syndrome and other genetic anomalies.
In the article, "The Amnio Alternative: New Test Could Diagnose Down Syndrome," Xenomics CEO Dr. Randy White discusses Xenomics' latest development efforts to produce breakthrough, improved methods of safely and accurately detecting prenatal Down syndrome, based on the Company's broad proprietary Transrenal-DNA (Tr-DNA) platform technology.
Xenomics' proprietary technology is now undergoing clinical research studies on human urine samples in major U.S. and European health centers, for the safe, effective and accurate diagnosis of conditions including Down syndrome, HIV, and Tuberculosis. If these studies demonstrate continued success, Xenomics could submit its first testing products to the Food and Drug Administration by 2007.
The article further reports, "In recent years, particularly as an increasing number of women choose to have children in their late 30s and 40s, science has come up with more tests to screen for certain genetic conditions, birth defects and other problems. Those tests, offered earlier in women's pregnancies, often spare women from deciding whether or not to undergo amniocentesis."
Writer Rachel Scheier also quotes Dr. White on the potentially substantial medical advantages provided by Xenomics' innovative testing platform. He believes Tr-DNA technology could revolutionize prenatal diagnostic testing, by providing an earlier and more accurate result than the currently available triple and quad screen tests and as a prescreen for amniocentesis to reduce the number of these potentially risky procedures performed.
This was only the latest in a series of news stories published about Xenomics' novel medical technology, including a major online CNN/Money feature recently on the Company's prospects for market success and commercialization of its Down syndrome testing kit. In that CNN/Money article, an independent, third party analyst, Sharon Rosen, is quoted in reference to Xenomics.
"If the company is successful on the risky road to getting a prenatal DNA urinalysis on the market, it could be a revenue boon," Ms. Rosen says. "If it works, whoa, it's like (the invention of the) printing press," she notes. "They've got a license to print money."
Xenomics is also developing new and medically valuable Tr-DNA tests for infectious diseases HIV, tuberculosis and malaria. The Company's Tr-DNA technology involves the analysis of fragments of DNA that have moved from the blood stream through the kidneys, where they accumulate in urine.
Xenomics' scientists were the first to detect this DNA material in urine samples. Most existing medical DNA diagnostic tests use blood or tissue samples from more invasive tissue biopsies, which are more difficult to obtain.
Herald News is part of the North Jersey Media Group, which provides "a broad spectrum of news and information products to serve the needs of diverse communities all across North Jersey." For more information, please visit www.northjersey.com.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html. Xenomics is listed on the Frankfurt Exchange under the symbol: (FWB:XE7).
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
